Genzyme Opts Out of Voyager Gene Therapy for Parkinson’s Disease – Genetic Engineering & Biotechnology News
|
Genzyme Opts Out of Voyager Gene Therapy for Parkinson's Disease
Genetic Engineering & Biotechnology News Voyager insisted that the decision did not signal an end to the companies' up-to-$845 million collaboration, launched in 2015. Voyager and Genzyme agreed to develop and commercialize new adeno-associated virus (AAV) gene therapies for CNS disorders. |
